Jacobs Elizabeth T, Giuliano Anna R, Martínez María Elena, Hollis Bruce W, Reid Mary E, Marshall James R
Arizona Cancer Center, University of Arizona, Tuscon 85724-5024, USA.
J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):533-7. doi: 10.1016/j.jsbmb.2004.03.063.
In the US, prostate cancer (PCa) has the highest incidence rate of all cancers in males, with few known modifiable risk factors. Some studies support an association between the Vitamin D metabolites, 1,25-dihydroxyvitamin D (1alpha,25(OH)(2)D(3)) and/or 25-hydroxyvitamin D (25(OH)D(3)), and prostate cancer, while others have yielded conflicting results. 1alpha,25(OH)(2)D(3) has anti-proliferative and pro-differentiating effects in prostate cancer cell lines, and levels of circulating 25(OH)D(3) may be important as PCa cells possess 1-alpha-hydroxylase activity. Using a nested case-control design, we evaluated whether plasma levels of 25(OH)D(3) and 1alpha,25(OH)(2)D(3) were associated with prostate cancer risk in participants from the Nutritional Prevention of Cancer (NPC) trial. With 83 cases and 166 matched controls, we calculated the adjusted odds ratios for increasing plasma levels of 25(OH)D(3) and 1alpha,25(OH)(2)D(3). Compared to the lowest tertile of plasma 25(OH)D(3) levels, the adjusted odds ratios were 1.71 (0.68-4.34) and 0.75 (0.29-1.91); the corresponding odds ratios for 1alpha,25(OH)(2)D(3) were 1.44 (0.59-3.52) and 1.06 (0.42-2.66). Given the pivotal effects of the Vitamin D receptor on gene transcription, it is likely that the anti-carcinogenic effects of Vitamin D that have previously been described are related to the activity and expression of the Vitamin D receptor and should be investigated further.
在美国，前列腺癌（PCa）是男性所有癌症中发病率最高的，已知的可改变风险因素很少。一些研究支持维生素D代谢物1,25 - 二羟基维生素D（1α,25(OH)₂D₃）和/或25 - 羟基维生素D（25(OH)D₃）与前列腺癌之间存在关联，而其他研究则得出了相互矛盾的结果。1α,25(OH)₂D₃在前列腺癌细胞系中具有抗增殖和促分化作用，并且由于前列腺癌细胞具有1 - α - 羟化酶活性，循环中的25(OH)D₃水平可能很重要。我们采用巢式病例对照设计，评估了来自癌症营养预防（NPC）试验的参与者血浆中25(OH)D₃和1α,25(OH)₂D₃水平是否与前列腺癌风险相关。在83例病例和166例匹配对照中，我们计算了血浆中25(OH)D₃和1α,25(OH)₂D₃水平升高的调整比值比。与血浆25(OH)D₃水平最低的三分位数相比，调整后的比值比分别为1.71（0.68 - 4.34）和0.75（0.29 - 1.91）；1α,25(OH)₂D₃的相应比值比分别为1.44（0.59 - 3.52）和1.06（0.42 - 2.66）。鉴于维生素D受体对基因转录的关键作用，先前描述的维生素D的抗癌作用可能与维生素D受体的活性和表达有关，应进一步研究。
